Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytarabine controlled-release - Pacira BioSciences

Drug Profile

Cytarabine controlled-release - Pacira BioSciences

Alternative Names: Cytarabine liposomal; cytarabine liposome injection - Pacira BioSciences; Cytarabine sustained-release; DepoCyt; DepoCyte; DepoFoam Encapsulated Cytarabine; DTC 101; NS-101 - Pacira BioSciences; Savedar

Latest Information Update: 12 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma Inc
  • Developer IRCCS San Raffaele; Mundipharma International; Pacira BioSciences; Pacira Pharmaceuticals
  • Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neoplastic meningitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lymphomatous meningitis; Meningeal carcinomatosis
  • No development reported Neoplastic meningitis
  • Discontinued B-cell lymphoma

Most Recent Events

  • 09 Apr 2021 Discontinued - Phase-II for B-cell lymphoma in Italy (Intrathecal) (Pacira BioSciences pipeline, April 2021)
  • 09 Apr 2019 Pacira Pharmaceuticals is now called Pacira BioSciences
  • 17 Jul 2017 No recent reports on development identified - Phase-II for B-cell lymphoma in Italy (Intrathecal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top